High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis

Frontiers in Oncology

Xinyi Xia¹  Pengping Li²  Mengyan Zhu³  Qianghu Wang³  Liangyu Li³  Rong Ding³  Bin Huang³  Jie Li³  Lingxiang Wu³  Zhi Zhang³  Kening Li³  Min Wu³  Wei Wu³  Ziyu Wang³  Tianyu Qu⁵  Qianqian Wang⁵  Zhihong Zhang⁶  Renhua Guo⁷ 

[1] Blood Transfusion, Wuhan Huoshenshan Hospital, Wuhan, China;Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China;Department of Bioinformatics, Nanjing Medical University, Nanjing, China;;Department of Laboratory Medicine &Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;Department of Thoracic Surgery, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research and Nanjing Medical University Affiliated Cancer Hospital, Nanjing, China;Institute of Laboratory Medicine, Jinling Hospital, Nanjing University School of Medicine, Southern Medical University, Nanjing, China;Joint Expert Group, Wuhan Huoshenshan Hospital, Wuhan, China;

关键词: COVID-19;    lung cancer;    ACE2;    single cell;    tmprss2;   

DOI  :  10.3389/fonc.2021.644575

来源: DOAJ

【 摘 要 】

BackgroundCoronavirus disease 2019 (COVID-19) has rapidly spread worldwide. Systematic analysis of lung cancer survivors at molecular and clinical levels is warranted to understand the disease course and clinical characteristics.MethodsA single-center, retrospective cohort study was conducted in 65 patients with COVID-19 from Wuhan Huoshenshan Hospital, of which 13 patients were diagnosed with lung cancer. The study was conducted from February 4 to April 11, 2020.ResultsDuring the course of treatment, lung cancer survivors infected with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) had shorter median time from symptom onset to hospitalization (P = 0.016) and longer clinical symptom remission time (P = 0.020) than non-cancer individuals. No differences were observed among indicators such as time from symptom onset to hospitalization and symptom remission time between medium-term and short-term survivors. The expression of ACE2 (P = 0.013) and TMPRSS2 (P <0.001) was elevated in lung cancer survivors as compared with that in non-cancer individuals.ConclusionsACE2 and TMPRSS2 levels were higher at resection margins of lung cancer survivors than those in normal tissues of non-cancerous individuals and may serve as factors responsible for the high susceptibility to COVID-19 among lung cancer survivors. Lung cancer patients diagnosed with COVID-19, including medium-term survivors, have worse outcomes than the general population.

【 授权许可】

Unknown